Plain-English translation of NCT07860047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two new approaches to treat prostate cancer that has come back after initial surgery or radiation. The first is a personalized vaccine (VAC-XS15-PC01) designed to train your immune system to recognize and attack cancer cells. The second is a bispecific antibody called CC-1 that works by connecting your immune cells directly to cancer cells. The study will test whether giving the vaccine alone, the antibody alone, or both together works best.
When prostate cancer returns after surgery or radiation, treatment options are limited. This medication is designed to harness the body's own immune system to fight cancer in a new way, potentially offering hope to patients who don't qualify for or haven't responded to standard treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three treatments: the vaccine alone (three injections given 4 weeks apart), the antibody alone (weekly injections for 12 weeks), or both treatments combined. Throughout the study, you'll have regular visits to receive your injections, have blood tests to check your PSA levels and immune response, and be monitored for any side effects. The study will track how well the treatment works and how safe it is for you.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Germany